LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 1 | B12 | 72 | hr | 1311 | 4874 | 4870 | 1.0008 | 1.0008 |
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 2 | B12 | 72 | hr | 1311 | 5342 | 4961 | 1.0767 | 1.0785 |
MDA-MB-231 | Sorafenib | 0.04 | uM | LJP6 | 3 | B12 | 72 | hr | 1311 | 4777 | 4973 | 0.9604 | 0.9585 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 1 | B11 | 72 | hr | 1311 | 4465 | 4870 | 0.9168 | 0.9103 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 2 | B11 | 72 | hr | 1311 | 4895 | 4961 | 0.9866 | 0.9860 |
MDA-MB-231 | Sorafenib | 0.12 | uM | LJP6 | 3 | B11 | 72 | hr | 1311 | 4564 | 4973 | 0.9176 | 0.9125 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 1 | B10 | 72 | hr | 1311 | 4609 | 4870 | 0.9464 | 0.9426 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 2 | B10 | 72 | hr | 1311 | 5207 | 4961 | 1.0495 | 1.0509 |
MDA-MB-231 | Sorafenib | 0.37 | uM | LJP6 | 3 | B10 | 72 | hr | 1311 | 4657 | 4973 | 0.9363 | 0.9327 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 1 | B09 | 72 | hr | 1311 | 4970 | 4870 | 1.0205 | 1.0215 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 2 | B09 | 72 | hr | 1311 | 5202 | 4961 | 1.0484 | 1.0499 |
MDA-MB-231 | Sorafenib | 1.11 | uM | LJP6 | 3 | B09 | 72 | hr | 1311 | 5070 | 4973 | 1.0193 | 1.0200 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 1 | B08 | 72 | hr | 1311 | 4535 | 4870 | 0.9312 | 0.9260 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 2 | B08 | 72 | hr | 1311 | 4888 | 4961 | 0.9852 | 0.9845 |
MDA-MB-231 | Sorafenib | 3.33 | uM | LJP6 | 3 | B08 | 72 | hr | 1311 | 4907 | 4973 | 0.9866 | 0.9860 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 1 | B07 | 72 | hr | 1311 | 4163 | 4870 | 0.8548 | 0.8409 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 2 | B07 | 72 | hr | 1311 | 4580 | 4961 | 0.9231 | 0.9183 |
MDA-MB-231 | Sorafenib | 10 | uM | LJP6 | 3 | B07 | 72 | hr | 1311 | 4560 | 4973 | 0.9168 | 0.9117 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 1 | I12 | 72 | hr | 1311 | 5195 | 5128 | 1.0130 | 1.0132 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 2 | I12 | 72 | hr | 1311 | 5232 | 5100 | 1.0259 | 1.0263 |
MDA-MB-231 | CP466722 | 0.04 | uM | LJP5 | 3 | I12 | 72 | hr | 1311 | 5402 | 5010 | 1.0781 | 1.0793 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 1 | I11 | 72 | hr | 1311 | 4984 | 5128 | 0.9719 | 0.9712 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 2 | I11 | 72 | hr | 1311 | 5042 | 5100 | 0.9886 | 0.9884 |
MDA-MB-231 | CP466722 | 0.12 | uM | LJP5 | 3 | I11 | 72 | hr | 1311 | 5152 | 5010 | 1.0282 | 1.0289 |
MDA-MB-231 | CP466722 | 0.37 | uM | LJP5 | 1 | I10 | 72 | hr | 1311 | 5069 | 5128 | 0.9884 | 0.9882 |